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Jean-Marie Saint-Remy1,2*
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Autoreactive CD4+ T cells recognizing islet-derived antigens play a primary role in type 
1 diabetes. Specific suppression of such cells therefore represents a strategic target 
for the cure of the disease. We have developed a methodology by which CD4+ T cells 
acquire apoptosis-inducing properties on antigen-presenting cells after cognate recog-
nition of natural sequence epitopes. We describe here that inclusion of a thiol-disulfide 
oxidoreductase (thioreductase) motif within the flanking residues of a single MHC class 
II-restricted GAD65 epitope induces GAD65-specific cytolytic CD4+ T cells (cCD4+ T). 
The latter, obtained either in vitro or by active immunization, acquire an effector memory 
phenotype and lyse APCs by a Fas–FasL interaction. Furthermore, cCD4+ T cells elim-
inate by apoptosis activated bystander CD4+ T cells recognizing alternative epitopes 
processed by the same APC. Active immunization with a GAD65 class II-restricted 
thioreductase-containing T cell epitope protects mice from diabetes and abrogates 
insulitis. Passive transfer of in vitro-elicited cCD4+ T cells establishes that such cells are 
efficient in suppressing autoimmunity. These findings provide strong evidence for a new 
vaccination strategy to prevent type 1 diabetes.
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inTrODUcTiOn
Although the initial event leading to type 1 diabetes remains elusive, many data converge, both in 
mice and in humans, to establish that T cell-mediated autoimmunity toward several pancreatic islet 
cell autoantigens plays a significant role in pathogenesis (1, 2). Activation of CD4+ T cells by pres-
entation of β-cell antigens by APCs in the pancreas (3) and the regional draining lymph nodes (4) 
represents a first step in the initiation of autoimmunity, leading to organ inflammation and ultimately 
β-cell destruction. A therapy targeting the initial step in antigen recognition would therefore carry 
the potential of significantly impacting disease progression, provided such control remains antigen 
specific (5). Antigen-specific therapy offers the superiority of being limited only to responses specific 
to antigens involved in the disease process without exposing the body to a status of lessened reactivity 
to other antigenic challenges. Indeed, general immune suppression can lead to increased risk of 
infection and tumor proliferation and requires lifelong treatment.
Numerous studies have demonstrated the efficacy of antigen-based therapies, including GAD65 
protein, peptides, or modified peptides, in preventing type 1 diabetes in non-obese diabetes (NOD) 
mice (6). These strategies are based either on a shift within CD4+ cells from a Th1 to a Th2 profile or 
on the induction of tolerance by the activation of regulatory T cells (Tregs). Previous attempts in this 
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direction have failed in clinical trials and no disease-modifying 
agent has reached the market so far. There is therefore a need for 
developing a new immune-modulating strategy.
CD4+ T cells can be polarized into a cytolytic phenotype, 
thereby acquiring the capacity to induce apoptosis in APCs after 
peptide–MHC class II cognate recognition. This can be achieved 
only after synapse formation and by increasing the strength of 
the synapse created with peptide–MHC complexes obtained 
by adding a thioreductase motif within the flanking residues 
of class II-restricted epitopes (7). Importantly, APC apoptosis 
prevents activation of CD4+ T cells to alternative epitopes of the 
autoantigen from which the peptide is derived or to epitopes of 
associated autoantigens. An immune response to multiple anti-
gens can therefore be prevented or suppressed. In addition, CD4+ 
T cells polarized into a cytolytic phenotype eliminate by apoptosis 
bystander CD4+ T cells provided they are activated at the surface 
of the same APC (8).
GAD65 is one of several β-cell antigens recognized by T cells 
and its importance in the pathogenesis of autoimmune diabetes 
has been repeatedly demonstrated (9, 10). Epitope selection was 
based on the previously described GAD65524–538 epitope as elicit-
ing a CD4+ T cell response (11) and peptide-binding predictor 
algorithms (e.g., Rankpep). GAD65528–538 was selected based on 
both its description in the literature and as a good MHC class II 
binder. We therefore used a synthetic peptide encompassing this 
class II-restricted GAD65 epitope to determine whether insertion 
of a thioreductase motif within flanking residues could prevent 
type 1 diabetes. We further evaluated whether this effect could be 
related to the induction of cytolytic CD4+ T cells. Experiments 
were carried out in the most commonly used spontaneous model 
of the disease, the NOD mouse.
MaTerials anD MeThODs
Mice
Female NOD/MrkTac mice were purchased from Taconic Europe 
(Laven, Denmark). Female proinsulin 2-deficient (Ins2−/−) NOD 
mice, generated by backcrossing proinsulin 2-deficient 129 mice 
onto the NOD background, were graciously provided by Boitard 
(INSERM, Institut Cochin, Paris, France). All animal care and 
experiments were conducted according to the Institutional 
Animal Care and Research Advisory Committee of the University 
of Leuven. According to the requirements of the experiment, mice 
were housed either in conventional animal facilities or in specific 
pathogen-free (SPF) conditions at the University of Leuven.
Peptides
Synthetic peptides encompassing a GAD65 class II-restricted 
epitope (e.g., GAD65528–538, KVAPVIKARMM reported as 
WTGAD65), the same epitope containing a thioreductase motif 
of the CxxC format, wherein C stands for cysteine and x for any 
amino acid in flanking residues (reported as CCGAD65), the loss-
of-function sequence where the CxxC motif is replaced by a AxxA 
motif, wherein A stands for alanine (reported as AAGAD65), 
a non-relevant hen egg lysozyme (HEL) class II-restricted 
epitope (NTDGSTDYGILQINSR reported as WTHEL), and 
the CxxC-containing counterpart (reported as CCHEL) were 
produced by solid phase Fmoc chemistry (Eurogentec, Liège, 
Belgium). Purity of ≥95% was verified by chromatography.
Peptide immunization and Diabetes 
Monitoring
Four-week-old female NOD mice were immunized with des-
ignated peptide in alum (Alum Imject®, Pierce, Rockford, IL, 
USA), using 50  μg of peptide, for four subcutaneous weekly 
injections. Diabetes development was monitored until 40 weeks 
of age by weekly blood glucose measurements with One Touch 
Vita® glucometer (LifeScan, Johnson & Johnson Company, 
Milpitas, CA, USA), and diabetes was diagnosed when blood 
glucose levels were ≥300 mg/dl on two consecutive measure-
ments (12).
induction and culture of antigen-specific 
cD4+ T cells
Female NOD mice were immunized by four subcutaneous injec-
tions of 50 μg peptide in alum at 1-week intervals; spleen CD4+ 
T cells were isolated 2 weeks after the last injection (CD4 T cell 
isolation kit, Miltenyi, Bergisch Gladbach, Germany). T cell-
depleted splenocytes (reported as APCs) (CD90.2 microbeads, 
Miltenyi) from naive female NOD mice were preloaded for 2 h 
with peptide (5  μM) and treated with Mitomycin-C® (Kyowa, 
Tokyo, Japan). CD4+ T cells were stimulated with APCs loaded 
with peptide in a T to APC ratio of 1:3 and cultured in enriched 
RPMI 1640 medium containing 5% FCS, 50 μM 2-ME and 200 μg/
ml Gentamicin (Invitrogen Life Technologies, Gent, Belgium). 
After 10–14 days, cells were restimulated in the same conditions 
but with 10 U/ml mouse IL-2 (Roche, Brussels, Belgium). All cells 
described as cCD4+ T cells were generated identically by isolating 
CD4+ T cells from CCGAD65-immunized mice and expanding 
them in vitro in the presence of CCGAD65-loaded APCs.
cell Proliferation
CD4+ T cells were cultured for 4 days with Mitomycin-C®-treated 
T cell-depleted splenocytes with the indicated amount of peptides. 
3H-thymidine (1 μCi/well, PerkinElmer, Zaventem, Belgium) was 
added for the last 18 h before scintillation counting.
cell staining
Fluorochrome-stained antibodies recognizing mouse CD3e 
(145-2C11), CD4 (GK1.5), CD8 (SK1), CD25 (PC61), CD27 
(LG.3A10), CD28 (37.51), CD44 (IM7), CD62-L (MEL-14), 
CD127 (SB/199), CD107a (1D4B), and GATA-3 (L50-823) were 
purchased from BD Biosciences (Erembodegem, Belgium). 
Fluorochrome-stained antibodies recognizing mouse Foxp3 
(FJK-16) and T-bet (4B10) were from eBioscience (Frankfurt, 
Germany). Intracellular staining for T-bet, GATA-3, and Foxp3 
was done with Foxp3 Staining Kit (eBioscience). All stainings were 
performed following manufacturers’ instructions. Samples were 
acquired on a FacsCantoII flow cytometer (BD Biosciences), and 
data were analyzed with FACSDiva™ software (BD Biosciences) 
and Weasel software (WEH Institute, Melbourne, VIC, Australia).
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Killing assay
Spleen B cells were isolated (B cell isolation kit, Miltenyi) and cul-
tured overnight in the presence of 25 μg/ml LPS (Escherichia coli 
055:B5, Sigma-Aldrich, Diegem, Belgium) to maintain sufficient 
cell survival and support antigen presentation. Dead cells were 
removed by Ficoll centrifugation (Lympholyte-M, Cedarlane 
Labs, Atlanta, GA, USA) and remaining B cells were stained with 
Cyto-ID Red long-term cell tracer kit (Enzo Life Sciences, Lausen, 
Switzerland) following manufacturers’ instructions. B cells were 
then cocultured for 18 h with CD4+ T cells (ratio B:T, 1:5) in the 
presence of indicated peptide (2 μM, added to the culture media). 
Annexin V APC was used to detect cell death in B cells (Annexin 
V detection kit, BD Biosciences) according to manufacturers’ 
instructions. Gated B cells were then analyzed for Annexin V 
binding on flow cytometer. For inhibition of granzyme-B (GZB) 
activity, Z-AAD-CMK (Calbiochem/Merck, Overijse, Belgium) 
was added at 20  μg/ml during the entire coculture period. 
Inhibition of FasL was performed with functional grade anti-
mouse CD178 antibody (clone MFL3, eBioscience) at 20 μg/ml 
during the coculture period.
Bystander suppression assays
Target CD4+ T cells were labeled with 125 nM CFSE (Molecular 
Probes Life Technologies, Gent, Belgium) for 8  min in PBS at 
37°C. The reaction was stopped by washing the cells with PBS-
containing 2% FBS. These labeled cells were cocultured for 72 h 
with cytolytic CD4+ T cells and splenic B cells used as APCs 
(ratio target cells:cytolytic cells:APCs, 1:2:4) in the presence of the 
indicated peptides (5 μM, added to the culture media). Apoptosis 
was measured with Annexin V staining as described for the APC 
killing assay.
adoptive Transfer of cD4+ T cells
Eight-week-old female NOD mice were immunized as described 
above with either AAGAD65 or CCGAD65. Two weeks after last 
injection, mice were sacrificed, and CD4+ T cells were isolated 
from spleen and expanded in  vitro. Cultured cells (2.105  cells/
mouse) were transferred by intravenous injection to 6-week-old 
naive female NOD mice.
histology
Pancreases were fixed and embedded in paraffin, and 5–6 μm sec-
tions were stained with H&E to assess inflammatory infiltrates of 
the islets. Pancreatic islets were scored for the extent of insulitis, 
as previously described: grade 0, no inflammation; grade 1, peri-
insulitis with inflammatory cells touching islet perimeters, but 
not penetrating; grade 2, inflammatory infiltration <25% of islet 
area; grade 3, inflammation >25% but <75% of islet area; and 
grade 4, inflammation >75% of islet area (end-stage insulitis). 
Insulitis index (II) was calculated as II = (0 × n0) + (1 × n1) + 
(2 × n2) + (3 × n3) + (4 × n4)/4 × (n0 + n1 + n2 + n3 + n4) 
(12). A minimum of 40 non-overlapping islets were observed per 
mouse. Images were acquired using Zeiss Axiovision 4.6 software 
on Leica DM RBE microscope equipped with a Zeiss AxioCam 
MRc5 digital camera.
statistical analysis
Data are expressed as mean and SD or SEM as specified. Statistical 
evaluation was carried out with Prism 6.0. Differences in disease 
incidence were assessed by Mantel–Cox log-rank test analysis. 
Non-parametric assays were used for evaluating differences 
between means (Mann–Whitney test and ANOVA for multiple 
comparison tests). Significance was considered at P < 0.05.
resUlTs
immunization with ccgaD65 inhibits the 
Development of Diabetes and abrogates 
insulitis in nOD Mice
Four-week-old female NOD mice were immunized with a 
peptide encompassing a class II-restricted GAD65 epitope and 
a thioreductase motif (CCGAD65) in conventional animal 
facilities. Glycemia was followed on a weekly basis until the age of 
40 weeks. Diabetes-free survival rate was significantly increased 
for immunized (82%) versus untreated controls (38%) at 40 weeks 
of age (Figure S1A in Supplementary Material).
Leukocytic infiltration of the pancreatic islets (insulitis) is the 
major histopathological feature of type 1 diabetes development 
(12). Figure S1B in Supplementary Material shows significantly 
reduced insulitis index (II) at 40  weeks in normoglycemic 
CCGAD65-immunized mice with a mean II of 0.10  ±  0.03 
(SEM) as compared to 0.45 ± 0.06 (SEM) for the untreated group. 
Notably, the immunized group benefits from a significantly higher 
number of insulitis-free islets with 75 ± 6% (SEM) intact islets as 
opposed to 34 ± 7% (SEM) in the untreated group, and 4 out of 
16 mice in the treated group show absolutely no signs of insulitis 
at 40 weeks of age (Figures S1B,C in Supplementary Material).
Diabetes onset in NOD mice can be affected by the microbial 
environment in the housing facility partly due to the interaction 
of the intestinal microbiota with the innate immune system (13, 
14). To ensure efficacy of our setting, this preliminary experiment 
was repeated with mice kept under SPF facilities (15). Control 
mice further included four distinct settings. The first group was 
immunized with a peptide in which the thioreductase activity 
was abolished by substitution of the two cysteines of the motif 
by alanines and referred to as loss-of-function peptide. The 
second group was immunized with a non-relevant CCHEL 
peptide. The third group received the adjuvant alone and the last 
group remained untreated. Only CCGAD65-immunized group 
showed a diabetes-free survival curve significantly different from 
untreated group. Indeed, 43% of mice receiving the CCGAD65 
peptide remained diabetes-free as opposed to 17% in untreated 
mice. All other groups were not significantly different from the 
untreated group (Figure  1A). Although diabetes incidence in 
CCGAD65-immunized was not statistically distinct from the 
other control groups, we systematically and repeatedly noted a 
lower incidence of diabetes in this group in comparison to the 
four other control groups. Histological assessment of inflamma-
tory infiltrate further confirmed this trend.
Similar to others, we observed a consistent difference for 
diabetes incidence and severity of insulitis infiltration between 
FigUre 1 | nOD mice immunized with ccgaD65 peptide in sPF 
animal facilities.  
 (Continued)
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CCGAD65 group, as opposed to 11% in AAGAD54 group, 11% 
in CCHEL group, 6% in alum group, and 8% in untreated group. 
Separating data in Figures 1B,C according to diabetes status do 
not modify the statistical superiority of CCGAD65 in diminish-
ing insulitis. Furthermore, this reduction in insulitis can been 
seen at earlier stages as well as in 40-week-old mice indicating a 
sustainable effect (Figure S2 in Supplementary Material).
Overall, these data strongly suggest that active immunization 
with a thioreductase-containing GAD65 epitope inhibits the 
development of type 1 diabetes in female NOD mice both in less 
restrained conventional and in SPF conditions and confirms that 
mice are indeed protected from the autoimmune attack at the 
level of the islet. In addition, it is demonstrated that treatment 
neither with the corresponding loss-of-function peptide, nor 
with the non-relevant thioreductase-containing peptide, nor with 
the adjuvant alone can reproduce such protection.
ccgaD65 Peptide elicits cD4+ T cells 
with a Unique Phenotype and cytolytic 
Properties
To establish that cCD4+ T cells were elicited by peptide immu-
nization, CD4+ T splenocytes were isolated from CCGAD65-
immunized female NOD mice and expanded in  vitro in the 
presence of CCGAD65-loaded APCs. Cells proliferated in the 
presence of either CCGAD65 peptide or the corresponding 
WTGAD65 peptide (Figure  2A). Of note, WTGAD65 peptide 
elicits a stronger response in CD4+ T cells. Indeed, although the 
antigenic stimulation is stronger with the CCGAD65 peptide, this 
leads to TCR degradation, which can be responsible for a weaker 
proliferation.
The phenotype at resting state, 14 days after last stimulation 
with CCGAD65-loaded APCs, was CD3+CD4+CD8−CD25+C
D44+CD62L−CD127−CD27−CD28−, indicative of an effector 
(a) Four-week-old female NOD mice received four subcutaneous injections of 
50 μg of peptide in alum with a 7-day interval. Mice were randomly divided in 
five cohorts of five groups each treated with the same immunization protocol. 
The first group was immunized with the CCGAD65 peptide in alum, the 
second with the loss-of-function AAGAD65 peptide in alum, the third group 
with the non-relevant CCHEL peptide in alum, the fourth group received alum 
alone, and the fifth group remained untreated. Results represent diabetes-
free survival rates at, from top to bottom at 40 weeks, 43% for CCGAD65-
immunized mice (n = 47), 38% for AAGAD65-immunized mice (n = 50), 35% 
for CCHEL-immunized mice (n = 23), 21% for alum-treated mice (n = 24), 
17% for untreated control group (n = 23), *P < 0.05 and P > 0.1 reported as 
NS (Mantel–Cox log-rank test). (B,c) Pancreatic sections of mice sacrificed 
after two consecutive weekly glycemia above 300 mg/dl or after remaining 
normoglycemic during 40 weeks were stained with H&E and insulitis was 
scored by examining a minimum of 40 islets per mouse. (B) Individual II are 
represented for each group with line representing mean index; from left to 
right, CCGAD65 peptide in alum (n = 46, mean II = 0.51), AAGAD65 peptide 
in alum (n = 47, mean II = 0.63), CCHEL peptide in alum (n = 21, mean 
II = 0.63), alum alone (n = 23, mean II = 0.67), and untreated (n = 19, mean 
II = 0.70). Statistical significance was calculated with Kruskal–Wallis ANOVA 
test, P < 0.0001 followed by Dunn’s multiple comparison test as noted, 
*P < 0.05. (c) Grading of insulitis of the various groups as indicated. 
Statistical significance was calculated based on insulitis-free islets with 
Kruskal–Wallis ANOVA test, P < 0.0001 and Dunn’s multiple comparison test 
as indicated, *P < 0.05.
FigUre 1 | continued
NOD females housed in conventional or SPF animal facilities 
(15). Thus, the overall IIs were much higher for mice maintained 
in SPF conditions. Importantly, however, the calculated indexes 
of the CCGAD65 group remained significantly lower (Figure 1B) 
and with a better preservation of insulitis-free islets as compared 
to all the control groups (Figure 1C) even under such conditions. 
Note the highest percentage of islets without insulitis at 22% in 
FigUre 2 | characterization of ccgaD65-induced cD4+ T cells. (a) 
The proliferative response of CCGAD65-induced CD4+ T cells (pooled from 
three previously CCGAD65-immunized mice) to either CCGAD65 peptide 
(continuous line) or the natural counterpart (WTGAD65, dashed line) was 
assayed after 72 h in cocultures with Mitomycine C®-treated T-cell-depleted 
splenocytes loaded with the indicated peptide concentrations. 3H-thymidine 
was added for the last 12 h of culture. Error bars represent 1 SD. Data from 
one experiment representative of three experiments performed in triplicate 
wells. (B) CD4+ T cells induced either with WTGAD65 peptide (left panels) or 
CCGAD65 peptide (right panels) were analyzed by FACS at day 10 of 
stimulation. Results are from one experiment representative of three 
independent experiments. Additional information can be found as Figures S3 
and S4 in Supplementary Material.
FigUre 3 | antigen-presenting cells are induced into apoptosis by 
ccD4+ T cells. Splenic B cells isolated by magnetic beads from naive female 
NOD mice and activated overnight with LPS were cocultured for 24 h with 
CD4+ T cells generated either with the natural GAD65 peptide (white 
histograms) or with the CCGAD65 peptide (all other columns) in the presence 
of the indicated peptide (2 μM). Vertical axis represents B cell apoptosis 
measured by Annexin V binding. Addition of antibody toward FasL is shown 
in hatched column 7, and inhibitor toward GZB is shown in cross-hatched 
column 8. Statistical significance was calculated with one-way ANOVA test, 
P < 0.0001 and Dunnett’s multiple comparison test as indicated, *P < 0.05. 
Error bars represent 1 SD. Data are representative of three independent 
experiments.
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memory phenotype. Some cells were positive for T-Bet and/
or GATA-3, but all were negative for Foxp3. The production of 
cytokines was essentially limited to IFNγ. This distinct phenotype 
was conserved even when cells were repeatedly stimulated 
in vitro with the WTGAD65 peptide, suggesting a terminal dif-
ferentiation. By contrast, the phenotype expressed by CD4+ T 
cells generated in a similar manner from mice immunized with 
the WTGAD65 peptide was CD3+CD4+CD8−CD25+CD44+C
D62L−CD127highCD27highCD28− (Figure  2B; Figures  S3 and S4 
in Supplementary Material). Altogether, this indicates that cells 
generated with a thioreductase-containing peptide are terminally 
differentiated effector T cells with a memory phenotype.
We further evaluated whether such CD4+ T cells had 
acquired cytolytic properties allowing them to induce apoptosis 
in GAD65-presenting APCs. CD4+ T cells generated with the 
CCGAD65 peptide or the natural peptide were cocultured with 
naive NOD mouse splenic B cells used as APCs to compare their 
cytolytic capacity (16). When using cells induced with the natural 
peptide, B cell apoptosis remained low at 15%. However, when 
using CCGAD65-induced cells, the rate of B cell apoptosis was 
increased, and this in the presence of either WTGAD65 (39%) 
or CCGAD65 peptide (48%). This indicates that CCGAD65-
induced cells are able to induce apoptosis in APCs presenting 
not only the CCGAD65 peptide but also the natural GAD65 
peptide as could be encountered in  vivo. B cell apoptosis was 
not increased in the absence of peptide (19%) nor when a non-
cognate CCHEL peptide was added (14%), confirming that this 
process remains antigen specific (Figure 3).
FigUre 4 | induction of apoptosis of bystander cD4+ T cells. CD4+ 
T cells isolated from female NOD mice previously immunized with WTGAD65 
peptide and expanded in vitro served as bystander CD4+ T cells. (a) These 
cells were CFSE stained and cocultured with APCs loaded with WTGAD65 
peptide (left column) showing basal mortality rate measured by Annexin V 
binding (vertical axis). cCD4+ T cells generated with CCGAD65 peptide were 
added to this coculture (right column). A control well was added in which the 
cCD4+ T cells were replaced with the same number of unlabeled CD4+ T cells 
generated with WTGAD65 (middle column). Error bars represent 1 SD. 
Statistical significance was calculated with one-way ANOVA test, P < 0.0001 
followed by Dunnett’s multiple comparison test as indicated, *P < 0.05. (B) 
Same CFSE-stained cell line was used in this setting in coculture with APCs 
and cCD4+ T cells generated with CCGAD65 in the presence of the indicated 
peptide and mortality was measured by Annexin V expression (vertical axis). 
Hatched column 4 shows the effect of FasL antibody addition to the 
coculture, cross-hatched column 5 shows addition of GZB inhibitor, and 
black column 6 shows combination of both blockers. Error bars represent 1 
SD. ****P < 0.0001 (One-way ANOVA test and Dunnett’s multiple comparison 
test). Data are representative of three independent experiments.
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Apoptosis can be induced by either the Fas–FasL pathway (7, 
17, 18) or by secretion of cytotoxic granules containing gran-
zymes (19). Addition of an antibody toward FasL showed limited 
but consistent effect by reducing apoptosis from 48 to 39% and 
GZB inhibitors partially restored B cell survival (31% apoptosis), 
pointing to a dual mechanism, with GZB showing the strongest 
effect (Figure 3). Assessing the full implication of FasL or GZB 
remained limited by the toxicity of the inhibitor itself. GZB 
involvement was further confirmed by qPCR after stimulation 
with APCs and the CCGAD65 peptide, with a 200-fold increase 
in GZB gene expression in cells exposed to the CCGAD65 peptide 
(Figure S5 in Supplementary Material).
The present results are in keeping with data reported elsewhere 
(7, 8) and confirm that CD4+ T cells acquire an effector memory 
phenotype together with cytolytic properties after exposure to 
cognate peptide containing a thioreductase motif.
cD4+ T cells stimulated with 
cxxc Peptides induce apoptosis 
in Bystander T cells
Conversion of naive and polarized CD4+ T cells to cCD4+ T 
cells and induction of apoptosis in antigen-presenting cells 
might not be sufficient to suppress autoimmunity. The question 
was therefore extended to bystander CD4+ T cells. In view of 
this description, bystander CD4+ T cells are considered as cells 
activated during the same pathological process. These cells are 
specific of either the same (auto) antigen, the same epitope, an 
alternative antigen or an alternative epitope. The underlying goal 
was to determine whether it was possible to suppress a polyclonal 
CD4+ T cell response using a single epitope from a single antigen.
To demonstrate that CCGAD65-generated cCD4+ T cells were 
able to induce apoptosis in bystander T cells, these cCD4+ T cells 
were cocultured with APCs and GAD65-specific effector CD4+ 
T cells, in the presence of WTGAD65 peptide, and showed that 
42% of effector cells were induced into apoptosis. This was not 
observed when cCD4+ T cells were replaced by effector CD4+ 
T cells (23% mortality) nor when effector cells were used alone 
without peptide or without cCD4+ T cells (26% mortality), 
excluding effector cell death by lack of stimulation (Figure 4A). 
Interestingly, cell division in target cells is not affected by 
replacing unlabeled effector cells with cCD4+ T cells (Figure S6 
in Supplementary Material). Furthermore, apoptosis was not 
induced when WTGAD65 peptide was omitted (27% mortality 
measured by Annexin V) or replaced by a non-cognate CCHEL 
peptide (27% mortality) as opposed to increased apoptosis when 
the cognate peptide is used (87% mortality). This indicates that 
cCD4+ T cells killed activated, but not resting bystander CD4+ T 
cells and that killing only occurred in a specific setting. Apoptosis 
is significantly reduced when antibody to FasL is added during 
the entire course of the coculture (66% mortality), but not when 
GZB inhibitor is added (85% mortality). No cumulative effect 
is seen when antibody to FasL and GZB inhibitor are combined 
(66% mortality) (Figure 4B).
Apoptosis of bystander CD4+ T cells was also seen when using 
effector CD4+ T cells specific for another epitope (GAD65532–543). 
When culturing CFSE-labeled GAD65532–543 specific effector cells 
together with our described cCD4 cells and APCs loaded with 
both epitopes, we observed bystander T cell apoptosis (74.67%) 
with Annexin V staining. Importantly, apoptosis was not induced 
when GAD65532–543 was omitted from the coculture.
Our data show that cCD4+ T cells elicited by exposure to 
peptides containing a thioreductase motif acquired the capacity 
FigUre 5 | nOD mice transferred with ccD4+ T cells induced by 
ccgaD65. Naive mice were passively transferred at 6 weeks of age with 
cCD4+ T cells (2 × 105) obtained from mice preimmunized with CCGAD65 
peptide (from 8 to 12 weeks and sacrificed at 15 weeks) and expanded 
in vitro with CCGAD65. Mice were followed up with weekly blood glucose 
measurements until 40 weeks of age. (a) Diabetes-free survival curves are 
shown for mice transferred with CCGAD65-generated CD4+ T cells (n = 11), 
compared to the group transferred with AAGAD65-generated CD4+ T cells 
(n = 12) as indicated, *P < 0.05 (Mantel–Cox log-rank test). (B) Pancreatic 
sections of normoglycemic mice at 40 weeks of age transferred either with 
CCGAD65-induced CD4+ T cells or AAGAD65-induced CD4+ T cells were 
stained with H&E and insulitis was scored for at least 40 islets per mouse. 
Left panel: vertical axis represents insulitis index for each mouse, line 
indicates mean per group, treated group (n = 8) was compared to control 
group (n = 4). Statistical significance was calculated using two-tailed 
Mann–Whitney, **P < 0.01. Right panel: vertical axis represents percentage 
of insulitis-free islets per mouse, line indicates mean per group. Treated group 
was compared to control, **P < 0.01 (two-tailed Mann–Whitney test).
FigUre 6 | Diabetes-free survival in female Ins2−/− nOD mice 
immunized with ccgaD65 peptide. In conventional animal facilities, 
4-week-old female Ins2−/− NOD mice received four weekly subcutaneous 
injections of 50 μg of CCGAD65 (n = 11) or AAGAD65 (n = 10) or CCHEL 
(n = 8) peptide in alum as indicated. Control group (n = 11) remained 
untreated. Blood glucose levels were monitored weekly up to 20 weeks of 
age. Vertical axis represents percentage of diabetes-free survival. Results 
from two independent experiments, *P < 0.05, **P < 0.005 (Mantel–Cox 
log-rank test).
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to induce apoptosis of activated bystander T cells and that this 
activity involved Fas–FasL interaction.
Transfer of ccD4+ T cells from ccgaD65-
Treated Mice Prevents Diabetes and 
insulitis in nOD Mice
Whether prevention of diabetes was attributable to GAD65-
specific cCD4+ T cells was evaluated in an adoptive transfer 
experiment. Figure 5A shows that the diabetes-free survival rate 
was significantly higher for mice (82%, n = 11) transferred at the 
age of 6 weeks with CD4+ T cells isolated from female NOD mice 
preimmunized with CCGAD65 peptide and expanded in vitro, as 
compared to control mice (33%, n = 12) receiving cells generated 
from mice immunized with the loss-of-function peptide. Of note, 
cells were phenotyped directly prior to transfer to exclude expan-
sion of unwanted cell lines, including CD8+ T cells.
This confirms that GAD65-specific cCD4+ T cells are indeed 
accountable for the observed clinical benefit. In addition, it shows 
that CD4+ T cells generated with the loss-of-function peptide 
do not elicit any protection against the disease. Mice receiving 
GAD65-specific cCD4+ T cells demonstrated both a drastic 
reduction in insulitis as mean insulitis index for treated group 
(n = 8) was 0.09 ± 0.02 (SEM) and 0.63 ± 0.01 (SEM) for the con-
trol group (n = 4) and a clear preservation of insulitis-free islets. 
Indeed, treated group had 83 ± 4% (SEM) insulitis-free islets as 
compared to the control group with 24 ± 7% (SEM) (Figure 5B).
immunization with ccgaD65 Peptide 
Prevents Diabetes in Ins2−/− nOD Mice
Ins2−/− NOD mice develop accelerated diabetes with an onset 
spanned from 9 to 15 weeks of age in female mice. Elevated inci-
dence of diabetes onset in this model is hypothesized to be related 
to altered recognition of proinsulin and enlarged T cell repertoire 
specific of insulin in the periphery. Evidence supporting this is 
the striking difference in anti-insulin autoantibodies with higher 
prevalence in Ins2−/− NOD mice as compared to Ins2+/+ NOD 
mice (20).
Four-week-old female Ins2−/− NOD mice were immunized 
with the indicated peptide, and glycemia was followed on a 
weekly basis until the age of 20  weeks. Diabetes-free survival 
rate was increased for CCGAD65-immunized mice (82%) versus 
AAGAD65-immunized mice (60%), CCHEL-immunized mice 
(25%), and untreated controls (27%) (Figure 6). Of note, immu-
nization with the non-relevant CCHEL peptide conferred no 
effect. Prevention of diabetes in this model is further supportive 
of the bystander effect, though this is not formally demonstrated.
DiscUssiOn
Type 1 diabetes is associated with substantial morbidity and 
mortality despite replacement therapy with exogenous insulin. 
Current therapies are neither curative nor antigen specific (21). 
Interfering with the autoimmune response at the level of effector 
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CD4+ T cell activation would fulfill these two conditions by 
providing early and specific intervention. Tregs are known for 
their suppressive and regulatory effects on effector cells and are 
therefore being intensively investigated for their potential to 
control autoimmune diseases (22, 23). Currently, however, their 
use is limited by the low frequency of antigen-specific cells and 
the difficulty to expand them both in vitro and in vivo.
An alternative and distinct subset of CD4+ T cells exerting 
cytolytic activity has been occasionally described over the last 
30 years, mostly in the setting of viral infection (24, 25). cCD4+ T 
cells could potentially be of use in controlling various diseases in 
which CD4+ T cells play a central role if conditions under which 
they can be generated were better understood. Our work over 
recent years has succeeded in identifying such conditions, based 
on inclusion of a thioreductase motif within flanking residues of 
class II-restricted T cell epitopes (7). This motif, which is charac-
teristic of dicysteinylated glutaredoxins (26), reduces the second 
domain of the CD4 molecule impacting adaptors of the immune 
synapse (27). This results in skewing the function and phenotype 
of the CD4+ T cells, which acquire apoptosis-induction activi-
ties on APCs presenting the cognate native epitope, as well as 
on bystander T cells that recognize alternative epitopes on the 
same APC. The net result of the double action, and the require-
ment for physical synapse between the cCD4+ T cells and the 
APC presenting the corresponding epitope, is suppression of the 
response toward the antigen from which the epitope has been 
derived (intramolecular epitope spreading) and presumably 
ongoing response toward alternative pathology-associated anti-
gens (intermolecular epitope spreading) (28).
The advantage of designing an epitope where the thioreductase 
motif is included within the flanking residues lies in the propen-
sity to leave the interface between MHC and TCR unchanged, 
thus ensuring maintenance of critical interactions (29–31) while 
gaining the capacity of modifying the nature of the response. This 
methodology contrasts with that of altered peptide ligands in 
which amino acid residues from within the MHC class II binding 
and TCR recognition sequence are mutated (6, 32). Indeed, we 
have shown that immunization with synthetic peptides encom-
passing class II-restricted epitopes and a thioreductase motif is 
efficient to elicit a population of cCD4+ T cells in various settings, 
including models of experimental asthma and of EAE (data not 
shown).
We show here that a class II-restricted epitope of GAD65, 
a key autoantigen involved in type 1 diabetes pathogenesis (9, 
10), administered by direct immunization to female NOD mice 
inhibits the development of diabetes (83% in untreated mice 
versus 57% in CCGAD65-treated mice) and reduces insulitis 
in association with induction of antigen-specific cCD4+ T cells. 
We further show that cCD4+ T cells constitute the likely active 
ingredient of such effects from passive transfer experiments.
Reduction of the severity of insulitis is the most striking find-
ing, which is strictly dependent on the presence of a pathology-
associated epitope and of the presence of a thioreductase motif. In 
our cohort, as in others (33), insulitis is present in virtually 100% 
of female NOD mice. Strikingly, up to 22% of CCGAD65-treated 
mice showed no evidence of insulitis and about 20% showed a 
mild degree of insulitis. These findings suggest that such mice 
preserve a full capacity of producing insulin even after prolonged 
observation (40 weeks).
The reasons as to why not all treated mice respond to therapy 
with a similar benefit are multiple. Immunization is initiated at 
week 4 and requires 4 weeks, whereas infiltration of islets with 
autoreactive CD4+ T cells is apparent in between 4 and 6 weeks of 
age (34). The model itself is heterogeneous, depending on a large 
number of factors, such as the nature of the microbiotoma (35), 
the degree of insulin sensitivity (36), and, possibly, the stochastic 
nature of the first triggering event (37). Of note, we carried out 
our experiments with GAD65, which is not expressed by beta 
cells unless under stress conditions.
Interestingly, mice treated with a loss-of-function epitope 
show a tendency toward increased frequency in diabetes-free 
animals, while showing no difference on insulitis as compared 
to control mice, and show no capacity to elicit CD4+ T cells with 
cytolytic capacity. Transfer experiments with cells elicited with 
loss-of-function epitope likewise show no difference in terms of 
frequency of diabetes-free animals at 40 weeks. These data point 
to a possible impact of loss-of-function epitope, which would 
match published results (38), but which is clearly distinct from 
the effects observed with peptides used in the present approach. 
One possibility remains that the pool of effector CD4+ T cells 
is reduced by overstimulation and activation-induced cell death 
(AICD) resulting from recurrent injections of an epitope in natu-
ral sequence (39), or that such peptides elicit Tregs (40).
The data reported here indicate that Fas–FasL interactions play 
a role in induction of apoptosis of activated bystander CD4+ T 
cells, while GZB is prominent for apoptosis of APC. Interestingly, 
apoptosis of bystander CD4+ T cells occurs only when such cells 
are activated on the same APC, illustrating the requirement for 
cell–cell contact and independence from cytokine production. As 
in Tregs, cCD4 T cells are resistant to apoptosis by mechanisms 
that are not yet fully understood. Strikingly, these cCD4+ T cells 
acquire a stable and terminal phenotype characteristic of differ-
entiated effector memory T cells.
Another parameter that was of concern for this study is the 
possible impact of the maintenance of animals in SPF facilities. 
It is known that the incidence of diabetes in the NOD mice is 
greatly enhanced by keeping mice under SPF conditions and 
many reasons have been raised to explain this (15). However, 
much less information exists on the effect of SPF conditions on 
insulitis. Our observations (unpublished), in keeping with oth-
ers, indicate that a more aggressive form of insulitis occurs under 
such conditions, due to, inter alia, increased number of NK cells 
and reduced number of Tregs. It was therefore of importance to 
demonstrate that our approach was efficient under free and SPF 
conditions.
CD4+ T cells might, however, not be the only T cell subset 
relevant to type 1 diabetes pathogenesis. A pathogenic role for 
CD8+ T cells in autoimmune diabetes has indeed been described 
(41, 42), possibly as an initiating event. We, however, suggest that 
eliminating CD4+ T cells using the present methodology could 
also prevent activation of CD8+ T cells.
A popular tenet in autoimmunity is that there could be one 
primary autoantigen that initiates pathogenesis. Tissue destruc-
tion through targeting of this antigen could further release 
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other ones, thus amplifying the autoimmune cascade through 
a phenomenon known as epitope spreading. Epitope spreading 
occurs once the disease process is triggered, and there is no doubt 
that several β-cell antigens, and not only GAD65, are involved 
in type 1 diabetes (6, 43). The present technology using a single 
epitope of a single β-cell antigen potentially prevents responses 
toward alternative epitopes and perhaps even alternative anti-
gens, provided the latter are presented by the same APC. This 
condition is easily achieved considering that the main site at 
which the cCD4+ T cells control the immune response is in the 
lymph nodes draining the diseased organ, a location at which 
much of the autoantigens released into the affected organs are 
processed for presentation to the immune system. As type 1 dia-
betes is a chronic progressive autoimmune disease evolving with 
an increasing number of autoantigens over time, the ability to 
impact multiple epitopes would represent a great asset. Efficacy 
in controlling diabetes onset in the Ins2−/− NOD mouse model 
defined by a T cell repertoire directed essentially toward insulin 
by immunization with a thioreductase-containing GAD65 
peptide further anticipates a bystander effect toward alternative 
antigens.
Although acknowledging the limitations of the NOD mouse 
strain to predict effects in humans, this spontaneous model 
remains, in our view, the best available preclinical whole animal 
system representative of human type 1 diabetes (44), namely, 
allowing us to examine long-term consequences of a therapy. 
Noticeably, while a short course of immunization was sufficient to 
sustain long-standing efficacy in a context of continuing exposure 
to islet cell antigens, no adverse effects on mouse general status 
were observed over the 40 weeks follow-up period.
cOnclUsiOn
Altogether, preclinical efficacy has been established in the NOD 
mouse model by assessing glycemia and insulitis after active 
immunization with CCGAD65 peptide or transfer of cCD4+ 
T cells induced with CCGAD65. Additionally, these cCD4+ T cells 
have been shown to induce apoptosis of the APC presenting 
the epitope and of bystander T cells. Consequently, the present 
approach offers a promising antigen-specific therapy for type 1 
diabetes patients without compromising their general immune 
status.
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